{"nctId":"NCT00764881","briefTitle":"Effects of SH T00658ID on Libido","startDateStruct":{"date":"2009-01"},"conditions":["Contraception","Libido"],"count":217,"armGroups":[{"label":"EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)","type":"EXPERIMENTAL","interventionNames":["Drug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)"]},{"label":"EE/LNG (Microgynon) + Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Microgynon","Drug: Placebo"]}],"interventions":[{"name":"EV/DNG (Qlaira, BAY86-5027, SH T00658ID)","otherNames":[]},{"name":"Microgynon","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* OC-associated female sexual dysfunction (FSD) for at least 3 months but no longer than one year and willingness to continue OC use but to switch to SH T00658ID or Microgynon\n* Combined score of the sexual desire and arousal domains of the FSFI questionnaire of 18 or below at screening and baseline\n\nExclusion Criteria:\n\n* Contraindications for oral contraceptive use, for example but not limited to: presence or history of venous or arterial thrombotic / thromboembolic events, hypertension, presence or history of severe hepatic disease","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)","description":"Change from Baseline FSFI domains in desire and arousal component scores at Cycle 6. The change in score ranges from -28 (worst) to 28 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.45","spread":"5.33"},{"groupId":"OG001","value":"5.98","spread":"6.22"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS)","description":"Change from Baseline FSFI domains in desire and arousal component scores at Cycle 6. The change in score ranges from -28 (worst) to 28 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.43","spread":"5.36"},{"groupId":"OG001","value":"6.37","spread":"5.86"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Desire) at Baseline","description":"Sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire at Baseline. The normalized score for those 2 questions ranges from 1.2 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.51","spread":"0.72"},{"groupId":"OG001","value":"2.39","spread":"0.74"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Desire) at Cycle 6","description":"Sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire at Cycle 6. The normalized score for those 2 questions ranges from 1.2 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.53","spread":"0.95"},{"groupId":"OG001","value":"3.52","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Desire)","description":"Mean change from Baseline to Cycle 6 in the sum of questions 1 and 2 on sexual desire on the FSFI Questionnaire. The change in the normalized score for those 2 questions ranges from -4.8 (worst) to 4.8 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.02","spread":"0.98"},{"groupId":"OG001","value":"1.11","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Arousal) at Baseline","description":"Sum of questions 3 to 6 on sexual arousal on the FSFI Questionnaire at Baseline. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"0.94"},{"groupId":"OG001","value":"2.77","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Arousal) at Cycle 6","description":"Sum of questions 3 to 6 on sexual arousal on FSFI Questionnaire at Cycle 6. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":"1.23"},{"groupId":"OG001","value":"4.05","spread":"1.35"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Arousal)","description":"Mean change from Baseline to Cycle 6 in the sum of questions 3 to 6 on sexual arousal on the FSFI Questionnaire. The change in the normalized score for those 4 questions ranges from -6 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.43","spread":"1.25"},{"groupId":"OG001","value":"1.24","spread":"1.53"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Lubrication) at Baseline","description":"Sum of questions 7 to 10 on lubrication on the FSFI Questionnaire at Baseline. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.56","spread":"1.44"},{"groupId":"OG001","value":"3.73","spread":"1.14"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Lubrication) at Cycle 6","description":"Sum of questions 7 to 10 on lubrication on the FSFI Questionnaire at Cycle 6. The normalized score for those 4 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.90","spread":"1.18"},{"groupId":"OG001","value":"4.81","spread":"1.46"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Lubrication)","description":"Mean change from Baseline at Cycle 6 in the sum of questions 7 to 10 on the FSFI Questionnaire. The change in the normalized score for those 4 questions ranges from -6 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.36","spread":"1.53"},{"groupId":"OG001","value":"1.04","spread":"1.91"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Orgasm) at Baseline","description":"Sum of questions 11 to 13 on orgasm on FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.97","spread":"1.41"},{"groupId":"OG001","value":"2.93","spread":"1.24"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Orgasm) at Cycle 6","description":"Sum of questions 11 to 13 on orgasm on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.22","spread":"1.52"},{"groupId":"OG001","value":"4.05","spread":"1.49"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Orgasm)","description":"Mean change from Baseline to Cycle 6 in the sum of questions 11 to 13 on orgasm on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -6 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.26","spread":"1.52"},{"groupId":"OG001","value":"1.06","spread":"1.65"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Baseline","description":"Sum of Questions 14 to 16 on satisfaction on the FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0.8 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":"1.06"},{"groupId":"OG001","value":"3.20","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Cycle 6","description":"Sum of questions 14 to 16 on satisfaction on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0.8 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.19","spread":"1.13"},{"groupId":"OG001","value":"4.26","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Satisfaction)","description":"Mean change from Baseline to Cycle 6 in the sum of questions 14 to 16 on satisfaction on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -5.2 (worst) to 5.2 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"1.24"},{"groupId":"OG001","value":"1.03","spread":"1.20"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Pain) at Baseline.","description":"Sum of questions 17 to 19 on pain on the FSFI Questionnaire at Baseline. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.34","spread":"1.78"},{"groupId":"OG001","value":"4.74","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Domain Score (Pain) at Cycle 6","description":"Sum of questions 17 to 19 on pain on the FSFI Questionnaire at Cycle 6. The normalized score for those 3 questions ranges from 0 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","spread":"1.53"},{"groupId":"OG001","value":"5.01","spread":"1.55"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Pain)","description":"Mean change from Baseline to Cycle 6 in the sum of questions 17 to 19 on pain on the FSFI Questionnaire. The change in the normalized score for those 3 questions ranges from -6 (worst) to 6 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"1.83"},{"groupId":"OG001","value":"0.22","spread":"1.89"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Total Score at Baseline","description":"The normalized FSFI total score was the weighted sum of the domain scores covering a range from 2 (worst) to 36 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"5.6"},{"groupId":"OG001","value":"19.8","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of FSFI Total Score at Cycle 6","description":"The normalized FSFI total score was the weighted sum of the domain scores covering a range from 2 (worst) to 36 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"6.5"},{"groupId":"OG001","value":"25.7","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in FSFI Total Score","description":"The change in the normalized FSFI total score ranges from -34 (worst) to 34 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"6.9"},{"groupId":"OG001","value":"5.7","spread":"7.8"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Baseline","description":"Validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The total score ranges from 0 (worst) to 52 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":"10.6"},{"groupId":"OG001","value":"27.5","spread":"10.2"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Cycle 6","description":"Validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The total score ranges from 0 (worst) to 52 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"10.2"},{"groupId":"OG001","value":"17.6","spread":"11.4"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Female Sexual Distress Scale (FSDS-R) Total Score","description":"Change from Baseline to Cycle 6 in the validated, 13-item scale (0=never to 4=always) that assesses subjective distress associated with sexual dysfunction in women. A decrease in the total score=decrease in frequency of the subjective distress symptom. The change in total score ranges from -52 (best) to 52 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"10.4"},{"groupId":"OG001","value":"-9.6","spread":"10.5"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Baseline","description":"Q-LES-Q (short version - 16 items) assessed at Baseline the degree of enjoyment and satisfaction during the past week taking everything into consideration on a 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.76","spread":"10.85"},{"groupId":"OG001","value":"68.47","spread":"11.98"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Cycle 6","description":"Q-LES-Q (short version - 16 items) assessed at Cycle 6 the degree of enjoyment and satisfaction during the past week taking everything into consideration on a 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.63","spread":"11.72"},{"groupId":"OG001","value":"72.48","spread":"10.57"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score","description":"Change from Baseline to Cycle 6 in the overall enjoyment and satisfaction experienced during the past week as scored on the QLES-Q (short version - 16 items). 1-5 scale (very poor, poor, fair, good, very good). The normalized score ranges from 0 (worst) to 100 (best). The change in the normalized score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"11.26"},{"groupId":"OG001","value":"4.12","spread":"10.71"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline","description":"The PGWBI measured at Baseline self-representations over the past 4 weeks of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the well-being of the participant","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.75","spread":"6.78"},{"groupId":"OG001","value":"67.98","spread":"7.36"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6","description":"The PGWBI measured at Cycle 6 self-representations over the past 4 weeks of intrapersonal affective or emotional states reflecting a sense of subjective well-being or distress. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the well-being of the participant","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.20","spread":"8.32"},{"groupId":"OG001","value":"69.86","spread":"6.95"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) Global Score","description":"Change from Baseline to Cycle 6 in the PGWBI Questionnaire's assessment of the participant's overall sense of well-being or distress. The response format used a 6-grade Likert scale and the change in the normalized PGWBI global score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":"8.11"},{"groupId":"OG001","value":"1.90","spread":"7.23"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Baseline","description":"Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":"15.7"},{"groupId":"OG001","value":"71.5","spread":"16.1"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6","description":"Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":"16.0"},{"groupId":"OG001","value":"74.1","spread":"15.6"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Anxiety","description":"Anxiety is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - Anxiety score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"14.9"},{"groupId":"OG001","value":"2.6","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline","description":"Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.20","spread":"11.38"},{"groupId":"OG001","value":"85.79","spread":"12.16"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6","description":"Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.24","spread":"13.15"},{"groupId":"OG001","value":"89.94","spread":"9.61"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Depressed Mood","description":"Depressed mood is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - depressed mood score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"13.17"},{"groupId":"OG001","value":"4.25","spread":"11.38"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline","description":"Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.88","spread":"9.05"},{"groupId":"OG001","value":"48.46","spread":"6.53"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6","description":"Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.41","spread":"6.63"},{"groupId":"OG001","value":"49.26","spread":"6.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Positive Well-being","description":"Positive well-being is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - positive well-being score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"9.81"},{"groupId":"OG001","value":"0.98","spread":"7.55"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline","description":"Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.40","spread":"9.35"},{"groupId":"OG001","value":"66.66","spread":"8.36"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6","description":"Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.95","spread":"9.53"},{"groupId":"OG001","value":"67.18","spread":"8.33"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Self-control","description":"Self-control is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - self-control score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"12.21"},{"groupId":"OG001","value":"0.71","spread":"9.84"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline","description":"General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.12","spread":"14.75"},{"groupId":"OG001","value":"81.00","spread":"13.74"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6","description":"General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.22","spread":"13.95"},{"groupId":"OG001","value":"81.17","spread":"13.31"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - General Health","description":"General health is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale the change in the normalized PGWBI general health score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"15.57"},{"groupId":"OG001","value":"-0.15","spread":"14.14"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline","description":"Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.27","spread":"10.81"},{"groupId":"OG001","value":"60.93","spread":"9.01"}]}]}]},{"type":"SECONDARY","title":"The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6","description":"Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the range of PGWBI scores were normalized from 0 to 100. The higher the score, the better the wellbeing of the participant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.83","spread":"9.46"},{"groupId":"OG001","value":"63.58","spread":"8.31"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Vitality","description":"Vitality is 1 of 6 dimensions of the PGWBI self-report questionnaire used to measure the subjective well-being or distress of the participant. The response format used a 6-grade Likert scale and the change in the normalized PGWBI - vitality score ranges from -100 (worst) to 100 (best).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.42","spread":"10.11"},{"groupId":"OG001","value":"2.65","spread":"10.07"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6","description":"CGI is used to collect information regarding the subject's total clinical experience. The assessment scale ranges from 0 to 7: (0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). The scale of 1, 2, and 3 were categorized as improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.1","spread":null},{"groupId":"OG001","value":"70.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Improvement in Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6","description":"In 1 section of the CGI the subject rates their total improvement and rate of satisfaction with sexuality during treatment. The assessment scale ranges from 0 to 7: (0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse). The scale of 1, 2, and 3 were categorized as improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"62.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by Vaginal pH at Cycle 6","description":"Vaginal pH (0 to 6) measured by subject using a pH indicator dipstick","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.053","spread":null},{"groupId":"OG001","value":"0.039","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.298","spread":null},{"groupId":"OG001","value":"0.294","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.521","spread":null},{"groupId":"OG001","value":"0.637","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.117","spread":null},{"groupId":"OG001","value":"0.029","spread":null}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline","description":"ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.54","spread":"0.55"},{"groupId":"OG001","value":"0.47","spread":"0.48"}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6","description":"ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.40"},{"groupId":"OG001","value":"0.25","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Atrophy Symptom Questionnaire (ASQ)","description":"ASQ consists of 5 items which define the status of the vagina. The response format uses a 4-point scale from 0 (none) to 3 (severe). The change in average score ranges from -3 (best) to 3 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.27","spread":"0.50"},{"groupId":"OG001","value":"-0.18","spread":"0.38"}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline","description":"The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH\\<4) to 3 (severe or pH5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.14"},{"groupId":"OG001","value":"0.38","spread":"0.26"}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6","description":"The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH\\<4) to 3 (severe or pH5).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.15"},{"groupId":"OG001","value":"0.31","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA)","description":"The VHA, performed by the Investigator during gynecological exam, is the average of 5 individual scores related to composition and appearance of the vagina (secretions, epithelial integrity, epithelial surface thickness, color, and pH) scored from 0 (no atrophy or pH\\<4) to 3 (severe or pH5). The change in average score ranges from -3 (best) to 3 (worst).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.01","spread":"0.18"},{"groupId":"OG001","value":"-0.06","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Days in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"10.1"},{"groupId":"OG001","value":"15.3","spread":"5.6"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Days in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to 180 during study treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":"8.2"},{"groupId":"OG001","value":"12.6","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the fist treatment cycle includes 2 bleeding episodes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.5"},{"groupId":"OG001","value":"3.3","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"1.6"},{"groupId":"OG001","value":"3.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Mean Length of Bleeding / Spotting Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.47","spread":"2.44"},{"groupId":"OG001","value":"4.42","spread":"1.36"}]}]}]},{"type":"SECONDARY","title":"Mean Length of Bleeding / Spotting Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.13","spread":"2.09"},{"groupId":"OG001","value":"4.03","spread":"1.17"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Bleeding / Spotting Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"4.7"},{"groupId":"OG001","value":"5.6","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Bleeding / Spotting Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"2.9"},{"groupId":"OG001","value":"4.7","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":"4.5"},{"groupId":"OG001","value":"2.2","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"2.4"},{"groupId":"OG001","value":"1.3","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Number of Spotting Only Days in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","spread":"7.8"},{"groupId":"OG001","value":"3.8","spread":"3.9"}]}]}]},{"type":"SECONDARY","title":"Number of Spotting Only Days in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":"6.0"},{"groupId":"OG001","value":"3.3","spread":"4.7"}]}]}]},{"type":"SECONDARY","title":"Number of Spotting Only Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.4"},{"groupId":"OG001","value":"0.4","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Number of Spotting Only Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.5"},{"groupId":"OG001","value":"0.4","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Mean Length of Spotting-only Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":"3.43"},{"groupId":"OG001","value":"2.79","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"Mean Length of Spotting-only Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.18","spread":"2.26"},{"groupId":"OG001","value":"3.23","spread":"2.46"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Spotting-only Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"3.5"},{"groupId":"OG001","value":"3.3","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Spotting-only Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"2.8"},{"groupId":"OG001","value":"3.7","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1","description":"Reference Period 1 is defined as Day 1 to Day 90 during study treatment and includes the initial bleeding episode that triggered the first intake of study medication, meaning that the first treatment cycle includes 2 bleeding episodes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.6"},{"groupId":"OG001","value":"1.0","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2","description":"Reference Period 2 is defined as Day 91 to Day 180 during study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"2.0"},{"groupId":"OG001","value":"0.8","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.2","spread":null},{"groupId":"OG001","value":"97.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.5","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null},{"groupId":"OG001","value":"8.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Withdrawal Bleeding Episodes at Cycle 1","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"2.4"},{"groupId":"OG001","value":"4.6","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Length of Withdrawal Bleeding Episodes at Cycle 3","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"2.6"},{"groupId":"OG001","value":"4.4","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Length of Withdrawal Bleeding Episodes at Cycle 6","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.4"},{"groupId":"OG001","value":"4.0","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1","description":"Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.8"},{"groupId":"OG001","value":"3.7","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3","description":"Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.8"},{"groupId":"OG001","value":"3.8","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6","description":"Intensity was rated as 1=spotting; 2=light; 3=normal or 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"1.0"},{"groupId":"OG001","value":"3.6","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"7.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.3","spread":null},{"groupId":"OG001","value":"53.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.7","spread":null},{"groupId":"OG001","value":"25.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":null},{"groupId":"OG001","value":"61.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.4","spread":null},{"groupId":"OG001","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6","description":"Withdrawal bleeding is bleeding that occurs when using oral contraceptives (OCs) caused by falling levels and/or taking away external source of estrogen and progestogen toward cycle end. Intensity rated on 4-point scale from 1=spotting to 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"26.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.8","spread":null},{"groupId":"OG001","value":"47.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Onset of Withdrawal Bleeding Episodes at Cycle 1","description":"Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"5.0"},{"groupId":"OG001","value":"3.4","spread":"2.3"}]}]}]},{"type":"SECONDARY","title":"Onset of Withdrawal Bleeding Episodes at Cycle 3","description":"Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"6.5"},{"groupId":"OG001","value":"3.6","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Onset of Withdrawal Bleeding Episodes at Cycle 6","description":"Onset of withdrawal bleeding was calculated from the end of the exposure to the progestogen component (Day 24 for EV/DNG and Day 21 for EE/LNG). Therefore the count for the onset started at each Cycle on Day 25 for EV/DNG and Day 22 for EE/LNG.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.7"},{"groupId":"OG001","value":"3.3","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.2","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":null},{"groupId":"OG001","value":"4.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding Episodes at Cycle 1","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.5"},{"groupId":"OG001","value":"0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding Episodes at Cycle 3","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"},{"groupId":"OG001","value":"0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding Episodes at Cycle 6","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.4"},{"groupId":"OG001","value":"0.1","spread":"0.3"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Intracyclic Bleeding Episodes at Cycle 1","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"3.4"},{"groupId":"OG001","value":"2.4","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Intracyclic Bleeding Episodes at Cycle 3","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"5.2"},{"groupId":"OG001","value":"2.8","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Maximum Length of Intracyclic Bleeding Episodes at Cycle 6","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.4"},{"groupId":"OG001","value":"5.0","spread":"5.7"}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding Days at Cycle 1","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.9"},{"groupId":"OG001","value":"0.1","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding Days at Cycle 3","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"2.9"},{"groupId":"OG001","value":"0.1","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Number of Intracyclic Bleeding Days at Cycle 6","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.4"},{"groupId":"OG001","value":"0.3","spread":"1.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null},{"groupId":"OG001","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"25.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens. Intensity rated on 4-point scale where 1=spotting; 2=light; 3=normal; and 4=heavy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With at Least 1 Intracyclic Bleeding Episode","description":"Intracyclic bleeding is any unexpected bleeding episode occurring in cyclical treatment regimens.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.1","spread":null},{"groupId":"OG001","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.9","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":106},"commonTop":["Headache","Influenza","Upper respiratory tract infection","Pharyngitis","Bronchitis"]}}}